| Title | Current Cancer Drug Targets |
| Standard Abbreviation | Curr. Cancer Drug Targets |
| Type of Publication | Journal |
| Discipline | Drug Discovery (Q2); Pharmacology (Q2); Cancer Research (Q3); Oncology (Q3) |
| Impact Score | 2.95 |
| SCImago Journal Rank (SJR) | 0.687 |
| h-index | 99 |
| Overall Rank | 7275 |
| Publisher Name | Bentham Science Publishers B.V. |
| Publication Country | United Arab Emirates |
| International Standard Serial Number (ISSN) | 15680096, 18735576 |
| Coverage and History | 2001-2022 |
| Best Quartile | Q2 |
| Total Citations Received (Last 3 Year) |
723 |
Current Cancer Drug Targets is a journal published by Bentham Science Publishers B.V.. This journal covers the area[s] related to Drug Discovery, Pharmacology, Cancer Research, Oncology, etc.
The coverage history of this journal is as follows: 2001-2022.
The rank of this journal is 7275. This journal's impact score, h-index, and SJR are 2.95, 99, and 0.687, respectively. The ISSN of this journal is/are as follows: 15680096, 18735576.
The best quartile of Current Cancer Drug Targets is Q2.
This journal has received a total of 723 citations during the last three years (Preceding 2022).
The latest impact score (IS) of the Current Cancer Drug Targets is 2.95. It is computed in the year 2023 as per its definition and based on Scopus data.
2.95
It is increased by a factor of around 0.2, and the percentage change is 7.27% compared to the preceding year 2021, indicating a rising trend.
The impact score (IS), also denoted as the Journal impact score (JIS), of an academic journal is a measure of the yearly average number of citations to recent articles published in that journal. It is based on Scopus data.
Impact Score 2022 of Current Cancer Drug Targets is 2.95. If a similar upward trend continues, IS may increase in 2023 as well.
| Year | Impact Score (IS) |
|---|---|
| 2023/2024 | Coming Soon |
| 2022 | 2.95 |
| 2021 | 2.75 |
| 2020 | 3.06 |
| 2019 | 2.60 |
| 2018 | 2.15 |
| 2017 | 2.20 |
| 2016 | 2.81 |
| 2015 | 4.16 |
| 2014 | 3.87 |
The h-index of Current Cancer Drug Targets is 99. By definition of the h-index, this journal has at least 99 published articles with more than 99 citations.
The h-index (also known as the Hirsch index or Hirsh index) is a scientometric parameter used to evaluate the scientific impact of the publications and journals. It is defined as the maximum value of h such that the given Journal has published at least h papers and each has at least h citations.
The International Standard Serial Number (ISSN) of Current Cancer Drug Targets is/are as follows: 15680096, 18735576.
The ISSN is a unique 8-digit identifier for a specific publication like Magazine or Journal. The ISSN is used in the postal system and in the publishing world to identify the articles that are published in journals, magazines, newsletters, etc. This is the number assigned to your article by the publisher, and it is the one you will use to reference your article within the library catalogues.
ISSN code (also called as "ISSN structure" or "ISSN syntax") can be expressed as follows: NNNN-NNNC
Here, N is in the set {0,1,2,3...,9}, a digit character, and C is in {0,1,2,3,...,9,X}
The Current Cancer Drug Targets is ranked 7275 among 27955 Journals, Conferences, and Book Series.
As per SJR, this journal is ranked 0.687.
SCImago Journal Rank is an indicator, which measures the scientific influence of journals. It considers the number of citations received by a journal and the importance of the journals from where these citations come.
The publisher of Current Cancer Drug Targets is Bentham Science Publishers B.V.. The publishing house of this journal is located in the United Arab Emirates. Its coverage history is as follows: 2001-2022.
Please check the official website of this journal to find out the complete details and Call For Papers (CFPs).
The International Organization for Standardization 4 (ISO 4) abbreviation of Current Cancer Drug Targets is Curr. Cancer Drug Targets. ISO 4 is an international standard which defines a uniform and consistent system for the abbreviation of serial publication titles, which are published regularly. The primary use of ISO 4 is to abbreviate or shorten the names of scientific journals using the technique of List of Title Word Abbreviations (LTWA).
As ISO 4 is an international standard, the abbreviation ('Curr. Cancer Drug Targets') can be used for citing, indexing, abstraction, and referencing purposes.
If your area of research or discipline is related to Drug Discovery, Pharmacology, Cancer Research, Oncology, etc., please check the journal's official website to understand the complete publication process.
There are several factors that influence the acceptance rate of any academic journal. Here are some critical parameters that are considered while calculating the acceptance rate:
The simplest way to find out the acceptance rate or rejection rate of a Journal/Conference is to check with the journal's/conference's editorial team through emails or through the official website.
The latest impact score of Current Cancer Drug Targets is 2.95. It is computed in the year 2023.
The latest h-index of Current Cancer Drug Targets is 99. It is evaluated in the year 2023.
The latest SCImago Journal Rank (SJR) of Current Cancer Drug Targets is 0.687. It is calculated in the year 2023.
The latest ranking of Current Cancer Drug Targets is 7275. This ranking is among 27955 Journals, Conferences, and Book Series. It is computed in the year 2023.
Current Cancer Drug Targets is published by Bentham Science Publishers B.V.. The publication country of this journal is United Arab Emirates.
This standard abbreviation of Current Cancer Drug Targets is Curr. Cancer Drug Targets.
Current Cancer Drug Targets is a journal published by Bentham Science Publishers B.V..
The scope of Current Cancer Drug Targets is as follows:
For detailed scope of Current Cancer Drug Targets, check the official website of this journal.
The International Standard Serial Number (ISSN) of Current Cancer Drug Targets is/are as follows: 15680096, 18735576.
The best quartile for Current Cancer Drug Targets is Q2.
The coverage history of Current Cancer Drug Targets is as follows 2001-2022.
Note: The impact score shown here is equivalent to the average number of times documents published in a journal/conference in the past two years have been cited in the current year (i.e., Cites / Doc. (2 years)). It is based on Scopus data and can be a little higher or different compared to the impact factor (IF) produced by Journal Citation Report. Please refer to the Web of Science data source to check the exact journal impact factor ™ (Thomson Reuters) metric.
| Journal/Conference/Book Title | Type | Publisher | Ranking | SJR | h-index | Impact Score |
|---|---|---|---|---|---|---|
| Journal of Academic Ethics | Journal | Springer Netherlands | 8920 | 26 | 2.28 | |
| European Union Politics | Journal | SAGE Publications Ltd | 2250 | 72 | 2.64 | |
| Journal of Business Finance and Accounting | Journal | Wiley-Blackwell Publishing Ltd | 3221 | 84 | 3.68 | |
| Journal of Applied Business Research | Journal | 23890 | 29 | 0.28 | ||
| Archives of Phytopathology and Plant Protection | Journal | Taylor and Francis Ltd. | 14852 | 29 | 1.14 | |
| Marine Biology Research | Journal | Taylor and Francis Ltd. | 13573 | 42 | 1.06 | |
| Transnational Corporations | Journal | UNCTAD United Nations Conference on Trade and Development | 6120 | 27 | 1.92 | |
| Natural Solutions | Trade Journal | Innovision Health Media | 28581 | 1 | 0.00 | |
| Exploration Geophysics | Journal | Taylor and Francis Ltd. | 16383 | 48 | 1.17 | |
| Proceedings of the ACM SIGKDD International Conference on Knowledge Discovery and Data Mining | Conference And Proceedings | 4334 | 192 | 0.00 |
| Year | Impact Score (IS) |
|---|---|
| 2023/2024 | Updated Soon |
| 2022 | 2.95 |
| 2021 | 2.75 |
| 2020 | 3.06 |
| 2019 | 2.60 |
| 2018 | 2.15 |
| 2017 | 2.20 |
| 2016 | 2.81 |
| 2015 | 4.16 |
| 2014 | 3.87 |
2.95
0.687
99
7275
